$PTGX News

Protagonist Therapeutics Reports Granting of Inducement Awards

BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178

Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity

Protagonist Therapeutics (NASDAQ:PTGX) Passes Minervini Trend Template and High-Growth Screen

Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173

Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate

Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup

Protagonist Therapeutics Reports Granting of Inducement Awards

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151

Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review

Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued

Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?

Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145